DENTSPLY SIRONA Inc.
12.86-0.21 (-1.61%)
Oct 29, 4:00:01 PM EDT · NasdaqGS · XRAY · USD
Key Stats
Market Cap
2.57BP/E (TTM)
-Basic EPS (TTM)
-4.68Dividend Yield
0.05%Recent Filings
8-K
SEC closes DENTSPLY probe
DENTSPLY SIRONA announced on October 14, 2025, that the SEC has closed its investigation into the company's financial reporting matters—stemming from employee allegations probed since March 2022—without recommending enforcement action. The firm fully cooperated after voluntarily self-reporting. SEC clears DENTSPLY SIRONA. This closure marks a significant favorable development, lifting regulatory overhang.
8-K
Retention grant for supply chain exec
DENTSPLY SIRONA's board approved a $2,000,000 retention stock option grant to Senior VP and Chief Supply Chain Officer Tony Johnson on September 19, 2025, rewarding his performance amid recent CEO and CFO transitions while securing his commitment for three more years. The options, split between standard and 110% exercise prices, cliff-vest on the third anniversary and expire after ten years. This bolsters supply chain stability during leadership flux.
8-K
Retains Wellspect after review
Dentsply Sirona completed its review of strategic alternatives for Wellspect Healthcare on September 8, 2025, opting to retain the business within its portfolio after considering sales to multiple parties. The decision promises greater financial and strategic value to stockholders, leveraging Wellspect's leadership in the $2 billion continence care market and mid-single digit organic sales growth in 2024. Yet, execution risks persist amid forward-looking uncertainties.
10-Q
Q2 FY2025 results
Dentsply Sirona's Q2 FY2025 net sales fell 4.9% y/y to $936M, with Essential Dental Solutions up 2.9% y/y on higher restorative volumes in Rest of World, while Orthodontic and Implant Solutions dropped 18.1% y/y due to Byte suspension and implant weakness. Gross margin edged up to 52.4% from lower manufacturing costs, yet a $235M goodwill and intangible impairment charge—driven by tariffs and competitive pressures in the US and Europe—flipped operating income to a $128M loss from $50M profit. Operating loss exceeded net loss by over 20%, mainly from $24M net interest expense. Cash climbed to $359M, with $55M operating cash flow and free cash flow of $4M (derived); total debt hit $2.4B including new $550M junior notes due 2055, but $700M revolver availability holds. Ongoing securities litigation poses a key risk.
8-K
Q2 sales dip, margins expand
Dentsply Sirona reported Q2 2025 net sales of $936 million, down 4.9% from $984 million last year, with constant currency sales dropping 6.7% amid U.S. weakness and implant declines. Yet adjusted EBITDA margin expanded to 21.1% from 17.5%, and adjusted EPS rose to $0.52 from $0.49, despite a $214 million net impairment charge from tariffs and competition. Leadership shifted with Dan Scavilla as CEO from August 1 and Matt Garth as CFO from May 30; the company issued $550 million in notes to boost liquidity. It reaffirmed FY25 guidance of $3.60-$3.70 billion in sales and $1.80-$2.00 adjusted EPS. Impairments signal segment risks.
IPO
Employees
Sector
Industry
ALC
Alcon Inc.
73.60-1.22
ALGN
Align Technology, Inc.
131.91-1.23
BDX
Becton, Dickinson and Company
181.52-2.69
HSIC
Henry Schein, Inc.
62.32-0.89
ISRG
Intuitive Surgical, Inc.
537.59-7.80
NVST
Envista Holdings Corporation
19.98-0.08
SOLV
Solventum Corporation
69.78-1.14
SONX
Sonendo, Inc.
0.26-0.15
TUTH
Standard Dental Labs Inc.
0.09+0.03
ZIMV
ZimVie Inc.
18.99+0.00